[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,76,108,132,161,191,220,258,282,305,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100585813","phase-3-dapagliflozin-for-long-covid-syndrome-100585813",false,"NCT06907251","Dapagliflozin for Long COVID Syndrome","DALCO","Inclusion Criteria:\n\n* 18 years of age or older and willing and able to provide informed consent\n* Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.\n* New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).\n* Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.\n\nExclusion Criteria:\n\n* History of diabetes\n* Prior heart failure\n* Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)\n* Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.\n* Women who are breastfeeding\n* Severe renal impairment (eGFR\\\u003C30mL\u002Fmin1.73m2)\n* Known history of allergy or hypersensitivity to dapagliflozin\n\nExclusion for optional MRI portion of the protocol:\n\n\\- Any contraindication to MRI","ALL","18 Years",{"count":19,"type":20},192,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.",[26,27,28],"COVID - 19","Long COVID Syndrome","SARS CoV-2",[30,31,32],"Covid-19","Long Covid syndrome","sars cov-2","NOT_YET_RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":20},"2026-09-01",{"date":41,"type":20},"2029-06-30",{"name":43,"class":44},"Ottawa Heart Institute Research Corporation","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100616960","does-taurine-supplementation-improve-vascular-function-and-orthostatic-responses-in-long-covid-100616960","NCT07312409","Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?","Inclusion Criteria:\n\n* Participants will have had symptoms of Long COVID post-infection for at least 3 months\n\nExclusion Criteria:\n\n* Inability to undergo tilt table testing for 5 minutes\n* Inability to transport selves to York University from their homes\n* Inability to speak English, or provide a translator\n* Blood clotting disorders","65 Years",{"count":54,"type":20},30,"12 Weeks","OBSERVATIONAL","Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-weeks of taurine supplementation (self-administered), on vascular function and the cardio\u002Fcerebrovascular responses to upright posture. We will measure resting vascular function with an EndoPAT device, resting heart rate variability, and the blood pressure, heart rate, and brain blood flow responses to 5 minutes of head-up tilt before and after weeks of taurine supplementation in LC. We hypothesize that the 12 weeks of supplementation will improve both resting vascular function and the responses to upright tilt. In turn, we hypothesize that symptoms will also improve (as measured by questionnaires).",[27],[60,61,62,63,64,65],"Taurine","Vascular","Long COVID","Orthostatic","Cerebrovascular","Heart rate variability","RECRUITING","2026-06-03",{"date":69,"type":37},"2026-06-05",{"date":71,"type":37},"2026-06-01",{"date":73,"type":20},"2027-12-31",{"name":75,"class":44},"York University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":45},"100640470","diaphragmatic-breathing-exercises-with-kots-currents-in-patients-with-long-covid-100640470","NCT07621588","Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID","Effects of Diaphragmatic Breathing Exercises Combined With Diaphragmatic Electrostimulation Using KOTS Currents in Patients With Long COVID: A Pilot Randomized Controlled Trial","KOTS-LC","Inclusion Criteria:\n\n* Men and women aged 18 to 65 years.\n* Medical diagnosis of Long COVID.\n* At least 2 months since SARS-CoV-2 infection.\n* Ability and willingness to provide informed consent.\n* Ability to participate in the assigned intervention and assessment procedures.\n\nExclusion Criteria:\n\n* Presence of a pacemaker.\n* History of epilepsy.\n* Pregnancy.\n* History of acute cardiac arrest.\n* Severe respiratory distress.\n* Use of a wheelchair.\n* Blurred vision.\n* Cyanosis.\n* Refusal to perform part or all of the treatment.\n* Incomplete or incorrectly completed questionnaires.",{"count":85,"type":20},10,[87],"NA","This study will evaluate the effects of diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents in patients with Long COVID. Participants will be randomly assigned to one of two groups. The control group will perform diaphragmatic breathing exercises, while the intervention group will perform diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents. The intervention will last three weeks, with two sessions per week. The study will assess respiratory function, quality of life, physical function, dyspnea, fatigue, and basal oxygen saturation.",[27,90],"Post-Acute COVID-19 Syndrome",[92,93,94,95,96,97,98],"Diaphragmatic Breathing","KOTS Currents","Russian Currents","Diaphragmatic Electrostimulation","Quality of Life","Respiratory Rehabilitation","Spirometry","2026-06-02",{"date":101,"type":37},"2026-06-04",{"date":103,"type":20},"2026-06",{"date":105,"type":20},"2026-07",{"name":107,"class":44},"Universidad Pontificia de Salamanca",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":45},"100602455","phase-2-a-study-to-examine-anktiva-for-the-treatment-of-covid-19-100602455","NCT07123727","A Study to Examine Anktiva for the Treatment of COVID-19.","Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID","Inclusion Criteria:\n\n* Age ≥ 18 and \\\u003C 70 years.\n* History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and\u002For a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Those with only suspected but unconfirmed infections are not eligible for this study.\n* Clinical evidence of Long COVID, as confirmed by the Investigator's assessment.\n\n  1. At least 2 symptoms or at least 1 severe symptom as assessed by the study team (see list) that are new or worsened since the time of a SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the PI. At least 2 symptoms from those listed here must be present: systemic symptoms (eg, fatigue, chills, post-exertional malaise), neurocognitive symptoms (eg, trouble with memory\u002Fconcentration (\"brain fog\"), headache, dysautonomia\u002Fpostural orthostatic tachycardia symptoms, dizziness, unsteadiness, neuropathy, sleep disturbance), cardiopulmonary symptoms (eg, chest pain, palpitations, shortness of breath, cough, fainting spells), musculoskeletal symptoms (eg, muscle aches, joint pain), gastrointestinal symptoms (eg, nausea, diarrhea). Although other symptoms (eg, skin rash, hair loss, trouble with smell\u002Ftaste, genitourinary symptoms) will be recorded and tracked, at least 2 core symptoms listed above must be present. Note: the 2 symptoms can be from within the same category (for example, brain fog and headache) AND\n  2. Symptoms must have been present for at least 60 days prior to screening. Symptoms that wax and wane must have been initially present at least 60 days prior to screening AND\n  3. Symptoms must be reported to be at least somewhat bothersome and to have an impact on quality of life and\u002For everyday functioning AND\n  4. At least 90 days have elapsed since the most recent suspected or confirmed SARS-CoV-2 infection and the time of screening. Note: suspected infections will be determined based upon assessment by the study Investigators.\n* Not currently hospitalized.\n* Body mass index (BMI) 18 to 50 kilograms\u002Fmeter squared (kg\u002Fm2), inclusive, at the time of screening.\n* In otherwise stable health, as assessed by the Investigator within 28 days prior to screening, based on medical history, physical examination, laboratory findings, and vital signs.\n* For male participants,\n\n  a. Participants with partners that are WOCBP are strongly advised to inform their partners and must agree to use effective contraception from study entry (defined as INT1) through 7 months after the last dose of study intervention. Participants with pregnant partners must agree to use condoms during vaginal intercourse from study entry (defined as INT1) through 14 days after the last dose of study intervention administration.\n* For female participants,\n\n  a. A female participant who engages in sexual intercourse with male partners is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies: i. Is not a WOCBP OR ii. All of the following apply:\n  1. Is a WOCBP and is using a contraceptive method from - 21 days from study entry (defined as INT1), during the study intervention period, and for at least 7 months after the last study intervention administration.\n  2. A WOCBP must have a negative urine pregnancy test within 24 hours prior to all doses of study intervention. If a urine pregnancy test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test must be negative.\n* Willingness and ability to comply with the study protocol. This includes reliable transportation and sufficient time to attend all visits.\n* Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Previously received a SARS-CoV-2 antiviral or monoclonal antibody 30 days prior to planned INT1 or plan to receive such treatment before exiting the study.\n* Plans to receive any investigational or approved vaccine or booster for SARS-CoV-2 within 14 days prior to plan to receive such treatment before exiting the study.\n* History of autoimmune disease including, but not limited, to celiac disease, rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.\n* Active cardiovascular disease, defined as known prior:\n\n  1. Myocardial infarction within 90 days of screening; OR\n  2. Coronary artery bypass procedure within 90 days of screening; OR\n  3. Current heart failure with reduced ejection fraction (\\\u003C45%); OR\n  4. Current pulmonary arterial hypertension.\n* Known stroke within 3 months prior to planned INT1.\n* Known active bacterial, fungal, viral, or other infection besides SARS-CoV-2 requiring treatment within the 14 days prior to INT1 and meeting criteria for systemic involvement upon review by the PI.\n* Major surgery within 3 months prior to planned INT1 or planned major surgery during the first 75 days following planned INT1.\n* History of unplanned hospitalization for \\>24 hours within 28 days prior to Screening.\n* Active or prior Hepatitis B (Hep B) infection (defined as Hep B core antibody (cAb) and\u002For Hep B surface antigen (sAg) positive. Note: Prior hepatitis B is exclusionary even in the absence of ongoing infection.\n* Active Hepatitis C (Hep C) infection (defined as Hep C Ab positive or indeterminate with detectable Hep C RNA). Note: Those with cured Hep C (Ab positive or indeterminate but negative Hep C RNA) will remain eligible.\n* Laboratory abnormalities including:\n\n  1. ANC \\\u003C 1,500 per mm3\n  2. Platelet count \\\u003C100,000 per mm3\n  3. Hemoglobin \\\u003C 9 d\u002FdL\n  4. Baseline AST or ALT \\> 1.5 × ULN\n  5. CrCl \\\u003C 50 (estimated glomerular filtration rate)\n* Known or suspected HIV infection.\n* End stage kidney disease requiring dialysis.\n* History of Type I or Type 2 Diabetes mellitus requiring systemic medication or insulin.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Moderate or severe immunocompromise, includes the following: (a) receiving active treatment for solid tumor or hematologic malignancy, including use of systemic chemotherapy for treatment of cancer within the year prior to screening, (b) prior solid-organ transplant with active immunosuppressive therapy, (c) CAR-T cell therapy or hematopoietic cell transplant, on immunosuppressive therapy or transplant within the prior 2 years, (d) primary immunodeficiency syndromes, advanced or untreated HIV infection (see above), (f) on active high-dose corticosteroids (ie, ≥ 20mg prednisone or equivalent daily per day for ≥ 2 weeks).\n* Known prior diagnosis of myalgic encephalomyelitis\u002Fchronic fatigue syndrome (ME\u002FCFS), preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known prior diagnosis of dysautonomia, preceding and not related to SARS-CoV-2 infection and not worsened since SARS-CoV-2 infection.\n* Known allergy to any components used in the formulation of the intervention.\n* History of anaphylaxis or similar significant allergic reaction to prescription or non-prescription drugs or food products. Similarly, the presence of severe atopic conditions as assessed by the PI represents a significant risk for allergic reaction.\n* Participation in a clinical trial with receipt of an investigational product within 28 days prior to planned INT1, except for exploratory PET imaging studies related to Long COVID.\n* Current alcohol or illicit drug use as determined by the Investigator to preclude participation.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.","70 Years",{"count":117,"type":20},40,[119],"PHASE2","This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.",[62,27,122],"Long Covid 19","2026-05-08",{"date":125,"type":37},"2026-05-13",{"date":127,"type":37},"2025-09-04",{"date":105,"type":20},{"name":130,"class":131},"ImmunityBio, Inc.","INDUSTRY",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":45},"100575018","phase-2-study-to-evaluate-the-efficacy-and-safety-of-plitidepsin-in-adults-with-post-covid-19-condition-pcc-100575018","NCT06766825","Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","Phase II Proof-of-concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","THALASSA","1. Male or female individuals 18 years old or older.\n2. Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test \\[polymerase chain reaction (PCR) or transcription mediated amplification (TMA)\\], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) or positive serology against SARS-CoV-2 N protein regardless vaccination status.\n3. 3 or more symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.\n4. Unable to perform all usual duties\u002Factivities, defined as grades 3 or 4 in PCFS (Annex 3).\n5. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.\n6. Having understood the information provided and capable of providing informed consent\n\nEXCLUSION CRITERIA\n\n1. Last SARS-CoV-2 vaccine dose during the previous 30 days.\n2. Patients with active uncontrolled infections.\n3. Patients infected by SARS-CoV-2 virus in the last 90 days prior to the screening visit.\n4. Patients receiving treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (Annex 1) throughout plitidepsin treatment period and until 24-h washout period.\n5. Pacients receiving chronic glucocorticoid therapy (high-dose corticosteroids \\[ie, 20 mg of prednisone daily or equivalent for ≥2 weeks)\n6. Any of the following cardiac conditions or risk factors:\n\n   * Cardiac infarction or cardiac surgery episode within the last six months 14\n   * History of known congenital QT prolongation;\n   * Known structural cardiomyopathy with abnormal left ventricular ejection fraction (LVEF) \\\u003C50%;\n   * Current clinical evidence of heart failure or acute cardiac ischaemia (New York Heart Association (NYHA) class III-IV).\n7. Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or contraindication to receive systemic glucocorticoids, antihistamine H1\u002FH2 receptor agents, or antiserotonine 5HT3 receptors drugs.\n8. Mast cell activation syndrome.\n9. Females who are pregnant (negative serum or urine pregnancy test required for all females of childbearing potential at screening) or breast-feeding.\n10. Females of childbearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) who are not using highly effective contraceptive methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin. Refer to Annex 2 for contraception requirements.\n11. Unable to consent and\u002For comply with study requirements, in the opinion of the investigator.\n12. Currently participating or participated in a clinical trial within the prior",{"count":141,"type":20},90,[119],"The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with a total of 135 +\u002F-3 days approximately between both periods.\n\nDuring the intervention period, four treatment cycles will be administered, scheduled every 15 days (every 2 weeks), with intravenous (IV) infusion over three consecutive days. After completing the intervention period, a 90-day (+\u002F-5) follow-up period will be conducted.\n\nSubjects in arm A will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31 and Days 43 to 45. Subjects in arm B will receive 1h-IV placebo 1 vial \u002Fday during the first two treatment periods and will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the last two treatment periods. Subjects in arm C will receive 1h-IV placebo 1 vial\u002Fday during the four treatment periods.",[145,27,146,147,62],"Post COVID-19 Condition","Persistent COVID-19","Persistent COVID Condition",[149,150,151,152],"SARS-CoV-2","COVID-19","Long COVID19","Plitidepsin","2026-04-02",{"date":155,"type":37},"2026-04-03",{"date":157,"type":37},"2025-02-07",{"date":39,"type":20},{"name":160,"class":44},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":171,"studyType":56,"phases":4,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100396593","improving-cardiovascular-risk-stratification-using-t1-mapping-in-general-population-100396593","NCT04444128","IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION","IMPReSSION","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. 18 years of age and over\n3. Absence of a valid clinical indication for CMR, and\u002For known or clinically relevant cardiac disease\n\nExclusion Criteria:\n\n* accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety and SmPC for contrast agent)",true,{"count":170,"type":20},6000,"5 Years","Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).",[174,175,176,177,27],"Myocarditis","Heart Failure","Myocardial Fibrosis","Vascular Inflammation",[179,180,181],"Inflammation","Remodeling","vascular inflammation","2026-01-02",{"date":184,"type":37},"2026-01-06",{"date":186,"type":37},"2016-11-15",{"date":188,"type":20},"2030-06-30",{"name":190,"class":44},"Johann Wolfgang Goethe University Hospital",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":45},"100617246","phase-2-immunoadsorption-in-autoimmune-long-covid-100617246","NCT07316127","Immunoadsorption in Autoimmune Long COVID","A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID","TURNLongCOVID","Inclusion Criteria:\n\n* Long COVID based on the WHO-criteria\n* PEM according to the DSQ-PEM\n* BELL's functionality score 20-70%\n* Good health prior to the long COVID diagnosis (WHO performance score 0)\n\nExclusion Criteria:\n\n* Medical history of clinically significant respiratory- or cardiovascular disease\n* Prior interventional cardiac procedure within 3 months prior to randomization\n* Active immunosuppresive treatment for systemic autoimmune disorders\n* Diabetes type 1\n* Solid organ malignancy in the last 5 years\n* Active psychiatric disorder currently under treatment by a psychiatrist\n* BMI \\> 35\n* Pre-existing fatigue\n* Poor performance score prior to the long COVID diagnosis (WHO performance \\>0)\n* Pregnancy or breastfeeding",{"count":200,"type":20},70,[119],"Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.\n\nThis study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months.\n\nThis research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.",[62,27,204,205],"Long COVID-19 Syndrome","Post COVID Syndrome",[207,208,209,210],"immunoadsorption","long COVID","post COVID","plasmapheresis","2025-12-18",{"date":213,"type":37},"2026-01-05",{"date":215,"type":20},"2026-01-01",{"date":217,"type":20},"2028-03-12",{"name":219,"class":44},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":228,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":230,"conditions":231,"keywords":236,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100592359","observational-study-of-intranasal-ivig-in-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-patients-undergoing-medical-tourism-100592359","NCT06992401","Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism","An Observational Study Collecting Real-World Data on Intranasal IVIG Treatment in Long COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Immunodeficiency Engaged in International Medical Tourism","IVIG-LC","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)\n* Laboratory-confirmed immunodeficiency, including one or more of the following:\n* Low serum IgG and\u002For IgA\n* Specific antibody deficiency\n* Low pneumonia titers\n* Elevated inflammatory markers (e.g., CRP, cytokines)\n* No active infections at the time of enrollment (bacterial, viral, or fungal)\n* Negative for Lyme disease and NMDAR antibodies\n* Willingness to provide informed consent for data collection and use\n\nExclusion Criteria:\n\n* Current or recent active infection (e.g., viral, bacterial, or fungal)\n* Use of immunosuppressive therapy within the last 3 months\n* Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded\n* Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded\n* Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded\n* Inability to comply with study assessments or procedures",{"count":229,"type":20},50,"This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting.\n\nParticipants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation.\n\nThe goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.",[232,62,233,27,234,235],"Post-Acute Sequelae of SARS-CoV-2 Infection","Long COVID Fatigue","COVID 19 Associated Coagulopathy","COVID-19 Vaccination",[237,238,239,240,241,242,243,244,245,246,247,248],"Intranasal IVIG","Real-world data","Medical tourism","Long COVID fatigue","Cytokine panel","Immunoglobulin therapy","Brain fog","Chronic inflammation","Real-world evidence","Global health","Post-viral syndrome","Immune recovery","2025-11-24",{"date":251,"type":37},"2025-12-02",{"date":253,"type":20},"2026-08-01",{"date":255,"type":20},"2029-07-15",{"name":257,"class":44},"Tamara C Tamas",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":280,"locationsCount":45},"100588377","phase-2-magnetic-resonance-analysis-of-neural-inflammatory-factors-and-external-stimulation-100588377","NCT06940609","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)","MANIFEST","Inclusion Criteria:\n\n1. aged 18-80\n2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List\n3. have \"brain fog\" or cognitive difficulties as one of the ongoing symptoms\n4. are fluent in English\n5. if taking psychotropic medications, have been on stable doses for the past month.\n\nExclusion Criteria:\n\n1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation\n3. history of ongoing substance\u002Falcohol dependence, to reduce confounding effects on diagnosis and brain imaging\n4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS\n5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study\n6. any condition that would prevent the subject from completing the protocol\n7. appointment of a legal representative, to avoid coercion of a vulnerable population\n8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings\n9. any contraindication to MRI\n10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.","80 Years",{"count":268,"type":20},60,[119],"The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are:\n\n* Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire.\n* Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation.\n\nResearchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms.\n\nParticipants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.",[62,27,204,272,273],"PASC","PASC Post Acute Sequelae of COVID 19","2025-07-11",{"date":276,"type":37},"2025-07-15",{"date":278,"type":37},"2025-07-07",{"date":41,"type":20},{"name":281,"class":44},"University of New Mexico",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":45},"100583990","osteopathic-manipulative-therapy-effects-on-post-acute-sequelae-of-covid-19-pasc-or-long-covid-100583990","NCT06883513","Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID","Osteopathic Manipulative Therapy(OMT) Effects on Post-Acute Sequalae of COVID-19(PASC)","Inclusion Criteria:\n\n* \\- Individuals must claim they have had a prior positive SARS-CoV-2 test at least 6-weeks before the consenting process to proceed with the study\n* Individuals must claim they have at least one of the following symptoms greater than 6-weeks post infection that is affecting their daily life(these symptoms correlate with the SBQ™-LC):\n\nSymptoms of Long Covid Inclusion Criteria:\n\n* Shortness of breath or Difficulty Breathing\n* Difficulty with Movement (balance or tremor)\n* Muscle Pain or stiffness\n* Changes in sexual desire\n* Worsening Generalized Pain\n* Difficulty with Sleep\n* Changes in Mood (anxiety or depression)\n* Changes in Erectile function (Biological males only)\n* Palpations (irregular heart beats)\n* Altered Taste\n* Changes in your Hair\n* Changes in urination\n* Dizziness\n* Altered Smell\n* Changes in Skin\n* Changes in bowels\n* Fatigue\n* Indigestion\n* Dry or irritated eyes\n* Changes in sweating\n* Difficulty with Cognition (memory or thinking)\n* Stomach Pain\n* Changes in menstruation (Biological females only)\n* Chills or shivering\n\nExclusion Criteria:\n\n* If anyone denies they have any of the above symptoms before consent, they will be excluded from the trial\n\n  * They will also be excluded from the trial if they have suffered any fractured bones in the last 3 months (this will further decrease risk to the patient as the patient will be moved by the physician during the treatment protocol)\n  * Participants who are enrolled in other Long-COVID trials that have an intervention during their participation in this trial will be excluded. However, if they have a history of enrollment in a long-covid trial that has no interventions during this trial, they will not be excluded based on their history of acquiring experimental treatment.",{"count":290,"type":20},20,[87],"This study is investigating the effects of using an Osteopathic Manipulative Therapy (OMT) treatment protocol that was shown to statistically improve smell in individuals suffering from Long-COVID olfactory (smell) dysfunction in a small single-blinded pilot trial conducted during 2021.\n\nThe questions this study is trying to answer are:\n\n1. Does this OMT protocol improve other non-smell related Long-COVID symptoms\n2. Do 2 OMT treatments improve Long-COVID symptoms more than 1 OMT treatment\n\nParticipants will:\n\n1. Week 1: Take an digital survey regarding their Long-COVID symptoms undergo Long-COVID OMT treatment or a placebo treatment\n2. Week 2: Take an digital survey regarding their Long-COVID symptoms then all will undergo Long-COVID OMT treatment\n3. Week 3: Take an digital survey regarding their Long-COVID symptoms\n4. Week 8: Take an digital survey regarding their Long-COVID symptoms",[294,272,27],"Long-COVID",[294,272],"2025-03-17",{"date":298,"type":37},"2025-03-19",{"date":300,"type":20},"2025-05-01",{"date":302,"type":20},"2025-07-03",{"name":304,"class":44},"University of Louisville",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":168,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":311,"targetDuration":312,"studyType":56,"phases":4,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":45},"100582503","evaluation-of-micrornas-and-vitamin-b12-expression-in-subjects-with-neurologic-symptoms-of-depression-anxiety-and-fatigue-in-long-covid-19-100582503","NCT06864156","Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19","Inclusion Criteria:\n\n* Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing.\n* With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 after three months from the first day of acute infection symptoms.\n\nExclusion Criteria:\n\n* Subjects who have presented symptoms of acute infection in the last twelve weeks.\n* Subjects who present diagnostic premorbid neurological alterations.\n* Subjects who do not have at least 2 doses of COVID-19 vaccine, with last application date equal or older than 3 months.",{"count":290,"type":20},"1 Day","At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. This project seeks to analyze some blood components of people with long COVID, such as microRNAs and vitamin B12, in order to identify the body processes that changed after COVID-19 and thereby design better therapies and diagnostic methods focused on each of them.\n\nThe hypothesis is that the expression of miR-21, -146a and -155 will be overexpressed as well as there will be a deficiency of vitamin B12 in serum in subjects suffering from long COVID with neurological symptoms of depression, anxiety and fatigue.",[62,27],[316,317,318,319,320,321],"anxiety","depression","fatigue","microRNAs","vitamin b12","long covid","2025-03-05",{"date":324,"type":37},"2025-03-07",{"date":326,"type":37},"2025-02-18",{"date":328,"type":20},"2025-07",{"name":330,"class":331},"Instituto Nacional de Rehabilitacion","OTHER_GOV",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":355,"locationsCount":45},"100579275","phase-2-effectiveness-of-a-personalized-in-home-telerehabilitation-program-on-self-care-in-patients-with-long-covid-100579275","NCT06822179","Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients with Long COVID","Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients with Long COVID: a Randomized Clinical Trial","RESPICARE","Inclusion Criteria:\n\n* Post COVID-19 condition: individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction\n* Between 18 and 75 years of age\n* Possibility of access and use of smartphone.\n* Ability to attend the clinic in person for an initial session.\n\nExclusion Criteria:\n\n* Patients with a history of respiratory or cardiovascular diseases prior to COVID-19, other acute or chronic diseases that may interfere with the study\n* Pregnancy\u002Fbreastfeeding\n* Those with contraindications to respiratory muscle training.","75 Years",{"count":268,"type":20},[119],"The goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme with monitoring via a mobile app produces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent COVID.\n\nThe main questions it aims to answer are:\n\n* Will a multimodal program (exercise with education) improve the self-management ability of patients with post-exertional malaise?\n* Does fatigue and quality of life will be improved in these patients?\n\nResearchers will compare an experimental breath program to a control standard care group to see if multimodal program works to treat post-exertion malaise.\n\nParticipants will:\n\n* Follow-up 12 weeks online sessions:\n\n  1 weekly synchronous online session + 1 scheduled asynchronous session + educational resources\n* Daily use of the app: daily log, education and questions",[27],[346,347,150,348,349],"post-acute COVID-19 syndrome","self-management","Rehabilitation","Exercise","2025-02-14",{"date":326,"type":37},{"date":353,"type":20},"2025-03",{"date":105,"type":20},{"name":356,"class":44},"CEU San Pablo University"]